CytoMed Therapeutics Limited (NasdaqCM: GDTC)
Health Care · Biotechnology · SG
$0.94
-1.46% today · -46.7% 1Y
CytoMed Therapeutics Limited (NasdaqCM: GDTC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.23M and employs 42 people.
Over the last twelve months the share price has lost 46.7%, trading between 0.68 and 3.68.
Tweenvest scores CytoMed Therapeutics Limited across four factors: quality 29/100, value 40/100. Its strongest factor is value.
GDTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.23M
- Revenue (TTM)
- $669.28K
- P/E
- —
- EPS
- -0.34
- Dividend yield
- —
- Beta (5Y)
- 0.05
- 52-week high
- $3.68
- 52-week low
- $0.68
- Avg volume (3M)
- —
- Shares outstanding
- 11.83M
- Employees
- 42
- Next earnings
- —
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
- ISIN
- SGXZ17669631
- Founded
- 2018
- Listed since
- Apr 14, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.